Profil
Marlies Sproll served as the Chief Scientific Officer at MorphoSys AG from 2000 to 2017.
Prior to that, she worked at Lanthio Pharma BV as a Member-Supervisory Board.
Dr. Sproll earned a doctorate degree from Max Planck Institute for Metals Research.
Ehemalige bekannte Positionen von Marlies Sproll
Unternehmen | Position | Ende |
---|---|---|
MORPHOSYS AG | Technik-/Wissenschafts-/F&E-Leiter | 15.04.2017 |
Lanthio Pharma BV
Lanthio Pharma BV Medical SpecialtiesHealth Technology Lanthio Pharma BV focuses on discovering and developing lantipeptides for the generation of novel peptide therapeutics. Its product is a lanthionine-stabilized specific agonist of the AT2 receptor, which has great potential in diseases where tissue protection is important, like fibrosis. The company was founded in 2010 and is headquartered in Groningen, the Netherlands. | Direktor/Vorstandsmitglied | - |
Ausbildung von Marlies Sproll
Max Planck Institute for Metals Research | Doctorate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
Börsennotierte Unternehmen | 1 |
---|---|
MORPHOSYS AG | Health Technology |
Private Unternehmen | 1 |
---|---|
Lanthio Pharma BV
Lanthio Pharma BV Medical SpecialtiesHealth Technology Lanthio Pharma BV focuses on discovering and developing lantipeptides for the generation of novel peptide therapeutics. Its product is a lanthionine-stabilized specific agonist of the AT2 receptor, which has great potential in diseases where tissue protection is important, like fibrosis. The company was founded in 2010 and is headquartered in Groningen, the Netherlands. | Health Technology |